Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study

Table 3

Change in intensity of symptoms from baseline to each visit for patients from the effectiveness population with moderate to severe LUTS at baseline.

	At baseline ( = 164)
	Moderate symptoms	Severe symptoms
At week 24 ( = 144)
( versus baseline)
No symptoms	0 (0%)	0 (0%)
Mild symptoms	34 (23.6%)	3 (2.1%)
Moderate symptoms	91 (63.2%)	10 (6.9%)
Severe symptoms	1 (0.7%)	5 (3.5%)
At week 48 ( = 137)
( versus baseline)
No symptoms	1 (0.7%)	1 (0.7%)
Mild symptoms	43 (31.4%)	1 (0.7%)
Moderate symptoms	75 (54.7%)	11 (8.0%)
Severe symptoms	3 (2.2%)	2 (1.5%)
At last available visit ( = 164)
( versus baseline)
No symptoms	1 (0.6%)	1 (0.6%)
Mild symptoms	51 (31.1%)	2 (1.2%)
Moderate symptoms	88 (53.7%)	14 (8.5%)
Severe symptoms	3 (1.8%)	4 (2.4%)

Bhapkar’s test for homogeneity.